FISH for HER-2
- 88377 - QTY (1)
- Breast Cancer (HER2/ERBB2) Gene Amplification
- FISH for HER2 (ERBB2)
- LSI 17p11
Cleveland Clinic Laboratories
|Volume||Type||Container||Collect Temperature||Transport Temperature||Special Instructions|
|2 slides||Slide (s), unstained||Clean container||N/A||Ambient||One formalin-fixed, paraffin embedded block containing representative tissue OR unstained 4 μm tissue sections on electrostatically charged slides containing representative tumor. Tissue must be fixed in formalin NOT B5 or PREFER fixative IHC data must be included when ordering HER2 FISH testing.|
|Ambient||Sample is formalin fixed and must not be fixed in Prefer or B5|
5 days per week
5 - 7 days
|Fluorescent In-Situ Hybridization (FISH)|
Breast cancer tissue: primary or metastatic. IHC data must be included when ordering HER2 FISH testing. Please note: based on the 2018 Focused Update to the ASCO/CAP guidelines for human epidermal growth factor receptor 2 testing in breast cancer (PMID:29846104), reflex testing using immunohistochemistry will be performed when the HER2 (ERBB2) FISH result is Group 2, 3, or 4. For these cases, the TAT will be extended by 3-4 days.
Interphase FISH analysis utilizing an enumeration probe for the ERBB2 (HER2) gene at 17q12, as well as a probe specific to the centromere of chromosome 17. Used to detect amplification of the ERBB2 (HER2) gene in human breast tissue specimens, and other tumors, both primary and metastatic. If no cells are available for analysis, no analysis charges will be incurred.
This assay has not been validated n decalcified tissues. Results should be interpreted with caution given the likelihood of false negativity on decalcified specimens. This assay is not validated for primary gastric tumors.